Arthritis, RheumatoidPhase 2NCT00634933
Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis
A Phase 2 study testing TRU-015, Methylprednisolone and Prednisone in people with Arthritis, Rheumatoid, run by Pfizer at 65 sites in 10 countries.
Trial summary
This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arthritis, Rheumatoid
- What is being tested?
- TRU-015, Methylprednisolone and Prednisone
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 222 participants
- Where
- 65 sitesin 10 countries
- Study dates
- Mar 2008to Oct 2012
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical diagnosis of active seropositive rheumatoid arthritis on a stable dose of methotrexate (7.5-25 mg weekly) for at least 12 weeks with or without a history of anti-TNF use.
Who cannot join
- Any prior use of rituximab or other B cell depleting agents.
- Any significant health problem other than rheumatoid arthritis
- Clinically significant laboratory abnormalities
Trial locations and contacts
65 sites in 10 countries.
65 sites in 10 countries
United States29 sites
Pfizer Investigational Site
Birmingham, Alabama, 35294-7201
Pfizer Investigational Site
Charlotte, North Carolina, 28210
Pfizer Investigational Site
Chicago, Illinois, 60612
Pfizer Investigational Site
Cincinnati, Ohio, 45245
Pfizer Investigational Site
Clarksburg, West Virginia, 26301
Pfizer Investigational Site
Dallas, Texas, 75231
Pfizer Investigational Site
Danville, Pennsylvania, 17822
Pfizer Investigational Site
Daytona Beach, Florida, 32117
Pfizer Investigational Site
Flowood, Mississippi, 39232
Pfizer Investigational Site
Grande Rapids, Michigan, 49546
Pfizer Investigational Site
Los Angeles, California, 90048
Pfizer Investigational Site
Los Angeles, California, 90095
Pfizer Investigational Site
Mayfield Village, Ohio, 44143
Pfizer Investigational Site
Minot, North Dakota, 58701
Pfizer Investigational Site
Ocala, Florida, 34474
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73112
Pfizer Investigational Site
Palm Harbor, Florida, 34684
Pfizer Investigational Site
Paradise Valley, Arizona, 85253
Pfizer Investigational Site
San Antonio, Texas, 78232
Pfizer Investigational Site
Santa Maria, California, 93454-6945
Pfizer Investigational Site
Santa Monica, California, 90404
Pfizer Investigational Site
Springfield, Illinois, 62704
Pfizer Investigational Site
St Louis, Missouri, 63110
Pfizer Investigational Site
State College, Pennsylvania, 16801
Pfizer Investigational Site
Syracuse, New York, 13210
Pfizer Investigational Site
Wexford, Pennsylvania, 15090
Pfizer Investigational Site
Wilkes-Barre, Pennsylvania, 18711-3762
Pfizer Investigational Site
Worcester, Massachusetts, 01605
Pfizer Investigational Site
Worcester, Massachusetts, 01608
Mexico8 sites
Pfizer Investigational Site
Culiacán, Sinaloa/Mexico, 80020
Pfizer Investigational Site
Guadalajara, Jalisco, 44100
Pfizer Investigational Site
Guadalajara, Jalisco, 44158
Pfizer Investigational Site
Guadalajara, Jalisco, 44650
Pfizer Investigational Site
Guadalajara, Jalisco, 44690
Pfizer Investigational Site
Mexicali, Baja California/Mexico, 21100
Pfizer Investigational Site
Mexico City, 06700
Pfizer Investigational Site
Morelia, Michoacán, 58070
Canada7 sites
Pfizer Investigational Site
Kelowna, British Columbia, V1W 4V5
Pfizer Investigational Site
Kelowna, British Columbia, V1Y 3G8
Pfizer Investigational Site
Kitchener, Ontario, N2M 5N6
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7N 0W8
Pfizer Investigational Site
Sydney, Nova Scotia, B1S 3N1
Pfizer Investigational Site
Trois-Rivières, Quebec, G8Z 1Y2
Pfizer Investigational Site
Winnipeg, Manitoba, R3A 1M3
Germany5 sites
Pfizer Investigational Site
Cologne, 50924
Pfizer Investigational Site
Essen, 45239
Pfizer Investigational Site
Vogelsang, Gommern, 39245
Pfizer Investigational Site
Würzburg, 97070
Pfizer Investigational Site
Würzburg, 97080
Romania5 sites
Pfizer Investigational Site
Bucharest, Romania, 020983
Pfizer Investigational Site
Bucharest, 011172
Pfizer Investigational Site
Bucharest, 020983
Pfizer Investigational Site
Cluj-Napoca, Romania, 400006
Pfizer Investigational Site
Iași, Iaşi, 700081
France3 sites
Pfizer Investigational Site
Montpellier, France, 34059
Pfizer Investigational Site
Paris, 75674
Pfizer Investigational Site
Toulouse, 31059
Hungary3 sites
Pfizer Investigational Site
Budapest, 1023
Pfizer Investigational Site
Debrecen, 4043
Pfizer Investigational Site
Nyíregyháza, 4400
Belgium2 sites
Pfizer Investigational Site
Brussels, 1200
Pfizer Investigational Site
Liège, 4000
Serbia2 sites
Pfizer Investigational Site
Belgrade, 11000
Pfizer Investigational Site
Niška Banja, 18250
About this study
Official title: A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate
This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.
- Conditions
- Arthritis, Rheumatoid
- Being tested
- TRU-015, Methylprednisolone, Prednisone
- Keywords
- active, rheumatoid, arthritis, anti CD20
- Medical subject headings
- Arthritis, Rheumatoid, Motor Activity, Arthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TRU-015Drug
IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
PrednisoneDrug
Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
TRU-015Drug
IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
PrednisoneDrug
Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
TRU-015Drug
IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
PrednisoneDrug
Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Experimental | Consists of Arms 1a and 1b Receives: Drug: TRU-015; Drug: Methylprednisolone; Drug: Prednisone |
| Arm 2 | Experimental | Consists of Arms 2a and 2b Receives: Drug: TRU-015; Drug: Methylprednisolone; Drug: Prednisone |
| Arm 3 | Placebo comparator | Consists of Arms 3a and 3b. Receives: Drug: TRU-015; Drug: Methylprednisolone; Drug: Prednisone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With an American College of Rheumatology 50% (ACR 50) Response at Week 24
ACR50 response: greater than or equal to (>=) 50 percent (%) improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ-DI]); and C-Reactive Protein (CRP).
Measured: Week 24
Secondary outcomes (18)
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
ACR20 response: >= 20% improvement in tender joint count; >= 20% improvement in swollen joint count; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (HAQ-DI); and CRP.
Measured: Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (HAQ-DI); and CRP.
Measured: Week 2, 4, 8, 12, 16, 20, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (HAQ-DI); and CRP.
Measured: Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Number of Tender Joints
The number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.
Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Number of Swollen Joints
The number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Measured: Baseline. Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Duration of Morning Stiffness
Duration of morning stiffness is defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (if none was present = 0; if morning stiffness was continuing, average of duration of stiffness over the past 3 days was reported; if stiffness persisted the entire day, 1440 minutes [24 hours*60 minutes] was recorded).
Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Visual Analogue Scale for Pain (VAS-pain)
100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 = no pain to 100 = worst possible pain.
Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Physician Global Assessment (PGA) of Disease Activity
Physician Global Assessment of Disease Activity was measured on a 0 to 10 point scale, where 0 = no disease activity and 10 = extreme disease activity.
Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Patient Global Assessment (PtGA) of Disease Activity
Measured using a 0-10 point scale, where 0 = no disease activity and 10 = extreme disease activity.
Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
General Health Visual Analog Scale (VAS)
100 mm line (VAS) marked by participant. Participants were asked, "How do you feel concerning your arthritis?" Total possible score range, 0 mm = very well to 100 mm = extremely bad.
Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Health Assessment Questionnaire Disability Index (HAQ-DI)
HAQ-DI: participant-reported assessment of ability to perform tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) hygiene; and 8) common activities over past week. Each item scored on 4-point Likert scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. The overall disability index computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Disease Activity Score Based on 28-joints Count (DAS28)
DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and participant's general health visual analog scale (scores ranging 0 [very well] to 100 mm [extremely bad]). DAS28 less than or equal to (=<) 3.2 = low disease activity, DAS28 greater than (>) 3.2 to 5.1 = moderate to high disease activity.
Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Measured: Baseline, Week 12, 24, 36, 52
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns utility value for each domain in the profile. Score is transformed and results in total score range -0.594 to 1.000; higher score indicates a better health state.
Measured: Baseline, Week 12, 24, 36, 52
Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Measured: Baseline, Week 12, 24, 36, 52
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
Measured: Baseline, Week 12, 24, 36, 52
Work Productivity and Activity Impairment Questionnaire: Rheumatoid Arthritis (WPAI-RA) Score
WPAI-RA consisted of 6 items, a binary question on current employment, 3 questions on hours of work and work-loss, and 2 questions based on 0-10 point scale to judge how RA affects productivity at work and outside of work (0 = no effect on work and 10 = completely prevented from working). Four scores are derived: percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health and percent activity impairment due to health. Total possible score range: 0 to 100, where 0 = no impairment and 100 = completely impaired.
Measured: Baseline, Week 12, 24, 36, 52
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1.
Measured: Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2008 (estimated)
- Study startMar 2008
- Primary completionFeb 2010
- Study completionOct 2012
Why it stopped: The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No safety reasons contributed to the termination of the study.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Arthritis, RheumatoidStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 222 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Trubion Pharmaceuticals/Emergent BioSolutions Inc.
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00634933
- Sponsor's protocol ID
- 3206K1-2203
- Other IDs
- B2051001
- Status last verified
- Feb 2013
- First submitted
- 5 Mar 2008
- Last updated
- 11 Mar 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Mar 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate
- ClinicalTrials.gov ID
- NCT00634933
- Acronym / sponsor ID
- 3206K1-2203
- Conditions
- Arthritis, Rheumatoid
- Keywords
- active, rheumatoid, arthritis, anti CD20
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No safety reasons contributed to the termination of the study.
- Enrolment
- 222 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Collaborators
- Trubion Pharmaceuticals/Emergent BioSolutions Inc.
- Study start
- Mar 2008
- Primary completion
- Feb 2010 (actual)
- Study completion
- Oct 2012 (actual)
- First posted
- 13 Mar 2008 (estimated)
- Results
- Posted 11 Mar 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Experimental | Drug: TRU-015, Drug: Methylprednisolone, Drug: PrednisoneConsists of Arms 1a and 1b |
| Arm 2 | Experimental | Drug: TRU-015, Drug: Methylprednisolone, Drug: PrednisoneConsists of Arms 2a and 2b |
| Arm 3 | Placebo comparator | Drug: TRU-015, Drug: Methylprednisolone, Drug: PrednisoneConsists of Arms 3a and 3b. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Clinical diagnosis of active seropositive rheumatoid arthritis on a stable dose of methotrexate (7.5-25 mg weekly) for at least 12 weeks with or without a history of anti-TNF use.
Key exclusion criteria (3 listed)
- Any prior use of rituximab or other B cell depleting agents.
- Any significant health problem other than rheumatoid arthritis
- Clinically significant laboratory abnormalities
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TRU-015IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms). | Drug | Arm 1 |
| MethylprednisoloneIV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms). | Drug | Arm 1 |
| PrednisoneOral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms) | Drug | Arm 1 |
| TRU-015IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms). | Drug | Arm 2 |
| MethylprednisoloneIV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms). | Drug | Arm 2 |
| PrednisoneOral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms). | Drug | Arm 2 |
| TRU-015IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b). | Drug | Arm 3 |
| MethylprednisoloneIV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b). | Drug | Arm 3 |
| PrednisoneOral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b). | Drug | Arm 3 |
Primary outcome
Percentage of Participants With an American College of Rheumatology 50% (ACR 50) Response at Week 24
Time frame: Week 24
ACR50 response: greater than or equal to (>=) 50 percent (%) improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ-DI]); and C-Reactive Protein (CRP).
18 secondary outcomes
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Time frame: Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Time frame: Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Number of Tender Joints
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Number of Swollen Joints
Time frame: Baseline. Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Duration of Morning Stiffness
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Visual Analogue Scale for Pain (VAS-pain)
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Physician Global Assessment (PGA) of Disease Activity
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Patient Global Assessment (PtGA) of Disease Activity
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
General Health Visual Analog Scale (VAS)
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Health Assessment Questionnaire Disability Index (HAQ-DI)
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Disease Activity Score Based on 28-joints Count (DAS28)
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
36-Item Short-Form Health Survey (SF-36)
Time frame: Baseline, Week 12, 24, 36, 52
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score
Time frame: Baseline, Week 12, 24, 36, 52
Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)
Time frame: Baseline, Week 12, 24, 36, 52
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score
Time frame: Baseline, Week 12, 24, 36, 52
Work Productivity and Activity Impairment Questionnaire: Rheumatoid Arthritis (WPAI-RA) Score
Time frame: Baseline, Week 12, 24, 36, 52
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
Time frame: Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Mar 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Arthritis, Rheumatoid
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
65 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing TRU-015, Methylprednisolone and Prednisone in people with Arthritis, Rheumatoid, run by Pfizer at 65 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 11 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 65 sites in United States, Mexico, Canada, Germany, Romania and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 11 Mar 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With an American College of Rheumatology 50% (ACR 50) Response at Week 24 (time frame: Week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2013.